DNA RNA and Cells

09 Feb 2021 Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration
09 Feb 2021 Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
08 Feb 2021 FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options
08 Feb 2021 AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
06 Feb 2021 Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
06 Feb 2021 U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
03 Feb 2021 Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases
03 Feb 2021 Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
03 Feb 2021 ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients
02 Feb 2021 BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy
02 Feb 2021 Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute
01 Feb 2021 Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
01 Feb 2021 Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
29 Jan 2021 Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
29 Jan 2021 Focus on solid tumors - Discontinuation of MDG1021 development program
29 Jan 2021 Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
28 Jan 2021 Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
28 Jan 2021 AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
28 Jan 2021 Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
22 Jan 2021 YESCARTA® Approved in Japan for Treatment of Patients with Relapsed/Refractory Large B-Cell Lymphomas
21 Jan 2021 Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
21 Jan 2021 Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform
20 Jan 2021 T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
20 Jan 2021 Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
20 Jan 2021 Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up